Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure
Takashi Tsutsui, MD*,
Takayoshi Tsutamoto, MD*,*,
Atsuyuki Wada, MD*,
Keiko Maeda, MD*,
Naoko Mabuchi, MD*,
Masaru Hayashi, MD*,
Masato Ohnishi, MD* and
Masahiko Kinoshita, MD*
* First Department of Internal Medicine, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Japan
View larger version (14K):
[in a new window]
|
Figure 1 Plasma oxidized low-density lipoprotein (oxLDL) concentration in 18 control subjects, 50 patients with mild congestive heart failure (CHF) (New York Heart Association [NYHA] functional class II) and 34 patients with severe CHF (NYHA functional class III or IV). Mild CHF = NYHA functional class II; severe CHF = NYHA functional class III or IV. Triangles = control subjects; solid circles = patients with dilated cardiomyopathy; open circles = patients with ischemic cardiomyopathy.
|
|
View larger version (21K):
[in a new window]
|
Figure 2 Correlation between the plasma level of oxidized low-density lipoprotein (oxLDL) and left ventricular ejection fraction (LVEF) (A), and the plasma level of norepinephrine (NE) (B).
|
|
View larger version (19K):
[in a new window]
|
Figure 3 The Kaplan-Meier survival (A) and cardiac event-free rate (B) plots for 84 patients with congestive heart failure subdivided into two groups according to the median level of oxidized low-density lipoprotein (oxLDL) (12.2 U/ml).
|
|
|
